Munich - Delayed Quote EUR

Amphastar Pharmaceuticals Inc (29A.MU)

21.25

+0.10

+(0.47%)

At close: April 30 at 8:00:48 AM GMT+2

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, ...

ACCESS Newswire yesterday

AMPH
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

StockStory 7 days ago

AMPH

AZO
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]

Insider Monkey 15 days ago

AMPH
2 Reasons to Like AMPH and 1 to Stay Skeptical

What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

StockStory 16 days ago

AMPH
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has had a rough three months with its share price down 35%. However, a closer...

Simply Wall St. 20 days ago

AMPH
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat ...

ACCESS Newswire 28 days ago

AMPH
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, ...

ACCESS Newswire last month

AMPH
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting with Amphastar Pharmaceuticals (NASDAQ:AMPH).

StockStory last month

AMPH

ANIP

VTRS
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th ...

ACCESS Newswire last month

AMPH
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

StockStory last month

VTRS

ANIP

AMPH
Amphastar Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Amphastar Pharmaceuticals ( NASDAQ:AMPH ) Full Year 2024 Results Key Financial Results Revenue: US$732.0m (up 14% from...

Simply Wall St. last month

AMPH
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Small Cap Pharma Stocks to Buy Now?

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against the other small cap pharma stocks. Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry Emily Field, Head of […]

Insider Monkey last month

AMPH

LLY
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds

On Thursday, Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents. Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. The company reported sales of $186.5 million, up 20% year over year, missing the consensus of $188.81 million. Jack Zhang, Amphastar’s Pre

Benzinga last month

AMPH
Amphastar Pharmaceuticals Inc (AMPH) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

Amphastar Pharmaceuticals Inc (AMPH) reports a 14% annual revenue increase and anticipates new product approvals, despite facing competitive pressures and margin declines.

GuruFocus.com last month

AMPH
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 2 months ago

AMPH
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of -4.17% and 1.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AMPH
Amphastar: Q4 Earnings Snapshot

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 96 cents per share. The specialty pharmaceutical company posted revenue of $186.5 million in the period, which also missed Street forecasts. Three analysts surveyed by Zacks expected $188.6 million.

Associated Press Finance 2 months ago

AMPH
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per share was 1.9% below analysts’ consensus estimates.

StockStory 2 months ago

AMPH
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024

Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for ...

ACCESS Newswire 2 months ago

AMPH
Amphastar Pharmaceuticals' (NASDAQ:AMPH) 15% CAGR outpaced the company's earnings growth over the same five-year period

It hasn't been the best quarter for Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) shareholders, since the share price...

Simply Wall St. 2 months ago

AMPH

Performance Overview

Return	29A.MU	S&P 500 (^GSPC)
YTD	-42.02%	-4.18%
1-Year	-45.16%	+12.31%
3-Year	-37.50%	+36.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amphastar Pharmaceuticals Inc (29A.MU)

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About

Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?

2 Reasons to Like AMPH and 1 to Stay Skeptical

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

Amphastar Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Small Cap Pharma Stocks to Buy Now?

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds

Amphastar Pharmaceuticals Inc (AMPH) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

Amphastar: Q4 Earnings Snapshot

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024

Amphastar Pharmaceuticals' (NASDAQ:AMPH) 15% CAGR outpaced the company's earnings growth over the same five-year period

Performance Overview